Estimaciones de analistas de Wall Street para Corcept Therapeutics Incorporated (CORT): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 14 |
| Mantener | 9 |
| Venta | 3 |
| Venta fuerte | 0 |
| Analistas totales | 26 |
| Calificación media (1-5) | 0.42 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-04 | $0.81 | ||
| 2026-07-29 | $0.36 | $0.02 | +1383.3% |
| 2026-04-30 | $-0.30 | $-0.11 | -172.3% |
| 2026-02-24 | $0.20 | $0.33 | -39.4% |
| 2025-11-04 | $0.16 | $0.18 | -11.1% |
| 2025-07-31 | $0.29 | $0.23 | +26.1% |
| 2025-05-05 | $0.17 | $0.17 | +0.0% |
| 2025-02-26 | $0.26 | $0.37 | -29.7% |
Ratios de valoración
| Ratio P/E | 213.00 |
| Precio / Valor contable | 16.54 |
| EV / EBITDA | 412.58 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $81.3M | $159.2M | $251.2M | $306.5M | $353.9M | $366.0M | $401.9M | $482.4M | $675.0M | $761.4M |
| Coste de Ventas | $2.1M | $3.6M | $5.2M | $5.5M | $5.6M | $5.3M | $5.4M | $6.5M | $10.9M | $13.0M |
| Beneficio Bruto | $79.3M | $155.6M | $246.0M | $301.0M | $348.3M | $360.7M | $396.5M | $475.9M | $664.2M | $748.4M |
| I+D | $23.8M | $40.4M | $75.2M | $89.0M | $114.8M | $113.9M | $131.0M | $184.4M | $246.9M | $254.9M |
| Generales y Administrativos | $45.2M | $62.4M | $81.3M | $100.4M | $105.3M | $122.4M | $152.8M | $184.3M | $280.3M | $448.7M |
| Gastos Operativos | $69.1M | $102.8M | $156.5M | $189.4M | $220.1M | $236.2M | $283.8M | $368.6M | $527.2M | $703.6M |
| Beneficio Operativo | $10.2M | $52.9M | $89.5M | $111.6M | $128.2M | $124.5M | $112.6M | $107.3M | $137.0M | $44.8M |
| EBITDA | $10.3M | $53.0M | $89.7M | $113.8M | $130.4M | $128.0M | $117.5M | $125.6M | $162.8M | $68.4M |
| Gastos por Intereses | $2.0M | $49000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | $8.1M | $52.8M | $92.2M | $116.7M | $131.6M | $125.0M | $116.2M | $124.6M | $161.5M | $66.5M |
| Impuestos | 0 | -$76.3M | $16.7M | $22.5M | $25.6M | $12.5M | $14.8M | $18.4M | $20.3M | -$33.2M |
| Beneficio Neto | $8.1M | $129.1M | $75.4M | $94.2M | $106.0M | $112.5M | $101.4M | $106.1M | $139.7M | $99.7M |
| BPA | $0.07 | $1.14 | $0.60 | $0.82 | $0.92 | $0.97 | $0.95 | $1.02 | $1.35 | $0.95 |
| BPA Diluido | $0.07 | $1.04 | $0.60 | $0.77 | $0.85 | $0.89 | $0.87 | $0.94 | $1.23 | $0.82 |
| Acciones en Circulación (Diluidas) | $116.1M | $124.5M | $126.7M | $122.6M | $124.2M | $126.0M | $116.0M | $111.7M | $113.5M | $120.0M |
Precio
| Precio | $114.86 |
| Capitalización | $12.4B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ABVX · AXSM · CAI · CYTK · HALO · JAZZ · MRUS
Explorar sector: Healthcare · Medical - Pharmaceuticals
Más secciones de CORT: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones